Reimbursed Care Access in Denmark

Psilocybin is not an authorized, reimbursed medicine in Denmark and access is restricted to approved clinical research protocols and hospital-based studies. Multiple Danish centres (for example University of Copenhagen/NOESIS and Bispebjerg Hospital) are participating in EU‑funded, multi‑site clinical trials (e.g., the PsyPal trial) that received ethical/CTR approval to study psilocybin‑assisted therapy in palliative/depressive indications; patient recruitment for Danish sites was reported to begin in early 2025. # #.

Because psilocybin is only in clinical trial pipelines in Denmark, there is no routine public reimbursement pathway; trial participants receive treatment within the research infrastructure. Any future licensed medicinal use and reimbursement would require EMA/European Commission marketing authorization or a national licensing route and subsequent inclusion in Danish reimbursement schemes (regional hospital budgets or pharmaceutical reimbursement lists) — none of which currently apply to psilocybin in Denmark as of the cited trial approvals. #.

Currently classified as a strictly controlled substance for non‑medical use in Denmark, with access for therapeutic use limited to approved clinical trials and research collaborations. There are no national clinical‑use authorizations or reimbursement pathways for MDMA‑assisted psychotherapy; access is limited to investigational study protocols run by research institutions or in cooperation with international trial sponsors (e.g., MAPS‑sponsored research networks). # #.

Therefore, outside approved research settings there is no authorized, reimbursed MDMA treatment available in Denmark.

Esketamine (Spravato®) is available in Denmark for treatment‑resistant depression under hospital/specialist administration and has been the subject of national clinical and health‑technology assessments; the Danish Medicines Council (Medicinrådet) has evaluated esketamine and published guidance and cost/benefit assessment data for its use in moderate‑to‑severe major depressive disorder with inadequate response to other treatments. #.

Practical access and reimbursement nuance: Spravato is distributed as a hospital/specialist product in Denmark (hospital supply channels) and Danish pharmacy listings indicate 'no automatic outpatient subsidy' for listed packagings (i.e., it is designated for hospital use and standard pharmacy co‑payment/subsidy does not apply to the retail packs shown). Individual regional hospital budgets or negotiated contracts (including confidential discounts) and local formulary decisions determine availability in each region; Medicinrådet documents indicate substantial per‑patient costs and that regional decision‑makers consider clinical benefit versus cost when authorising use. # #.

In short: esketamine is an authorised, hospital‑delivered treatment in Denmark for certain treatment‑resistant depressive indications with health‑technology evaluation and use controlled at regional/hospital level; routine outpatient pharmacy reimbursement is not provided for standard retail packs.

Ketamine (racemic ketamine) is a licensed anaesthetic in Denmark and is used widely in clinical settings for anaesthesia and analgesia; specific low‑dose, repeated ketamine infusion protocols for treatment‑resistant depression are practised off‑label within specialist psychiatric and hospital settings and are the subject of ongoing research and limited clinical programmes. Clinical guidance and local hospital policies govern off‑label use and the prescribing clinician bears responsibility for such off‑label indications. # #.

Research and implementation nuance: Danish hospitals and research centres (e.g., Rigshospitalet) have active studies and pilot clinical uses exploring ketamine for acute neuroprotection, depression and other indications; such use is typically hospital‑funded or provided under research protocols and is not covered as a standard reimbursed outpatient psychiatric medicine by Denmark’s public pharmacy subsidy system. Recent Danish news reports and hospital press releases describe expanding hospital‑based ketamine programmes and trials rather than broad public reimbursement. #.

Currently classified as a strictly controlled substance under Danish drug law (Euphoric Substances Act / national scheduling), with importation, manufacture, sale and possession criminalised except within approved clinical research. The plant materials used in preparations such as ayahuasca are not always separately scheduled, but the active constituent DMT is explicitly listed and illegal in Denmark; possession, distribution and production of DMT are criminal offences except as authorised for approved research. #.

Currently classified as a strictly controlled substance under national scheduling and functionally illegal for medical use outside approved clinical research; there is no authorised therapeutic pathway or reimbursement for 5‑MeO‑DMT in Denmark. (Standard legal/availability position for synthetic tryptamines in Denmark.) #.

Currently classified as a strictly controlled substance under national drug scheduling with no authorised medical use or reimbursement outside approved clinical research. There is no regulated ibogaine treatment or public reimbursement pathway in Denmark. #.

Plant decoctions such as ayahuasca occupy a legal grey area in Denmark: the plant material itself is not specifically scheduled in the same way as isolated DMT, but because DMT (the active molecule) is explicitly illegal, importation, preparation or distribution of ayahuasca that contains DMT can create criminal liability under the Euphoric Substances Act. Practically, this means ayahuasca ceremonies are legally risky and not an authorised, reimbursed medical treatment in Denmark; any therapeutic use would have to be carried out within an approved research protocol. #.

Mescaline and mescaline‑containing cacti are controlled substances (or controlled by virtue of the active molecule) under Danish drug law; mescaline has no authorised medical indication or reimbursement in Denmark and is only accessible within approved clinical research. #.

Currently classified as a strictly controlled/forbidden class of new psychoactive substances under the Danish Euphoric Substances Act and related amendments (group bans covering 2C‑series substances); there is no authorised medical use or reimbursement and access is limited to approved clinical research where permitted. #.